Business Wire

OBILET

Share
European Online Travel Champion obilet.com Ready for Record Growth

obilet.com, Turkey’s premier online travel ticketing platform, is set to enjoy rapid growth in the wake of the Covid-19 pandemic. Having just acquired its arch-rival Biletall, Obilet is forecast to sell more than 20 million tickets in 2021 – up from 8 million in 2020 – and close out the year with $300 million GMV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005055/en/

Thanks to its unique offerings and innovative business model, the Istanbul-based travel-tech firm is now poised to expand its geographic reach amid an expected post-Covid global recovery.

SaaS-Powered Business Model

Already known throughout the region for its enormously popular ticket-booking app, Obilet’s primary distinction lies in its SaaS (Software-as-a-Service) powered business model. Obilet, invested in by EarlyBird and EBRD, provides bus operators with a best-in-class Ticket Management System (TMS) featuring 24/7 technical support. The company thereby creates a “lock-in effect” for its business operations on the supply side.

By distributing its portfolio of bus operators using its SaaS to other online ticketing platforms on a revenue-sharing basis, Obilet adds additional revenue streams on top of its lucrative B2C sales.

One of the world’s top-10 platforms for online bus and flight tickets, obilet.com saw remarkable growth in the pre-Covid-19 2016-2019 period, boasting a compound annual growth rate (CAGR) of 77%.

Biletall Buyout Cements Leading Position

Earlier last month (July 12), Obilet cemented its regional position by acquiring Biletall, its chief B2C and B2B competitor, which since the 2000s had played a pioneering role in the digitalization of Turkey’s travel industry. Although Obilet stole the top spot from Biletall in 2016 on the B2C side, Biletall nevertheless retained its leading position at B2B coverage.

The acquisition will give Obilet 100% destination coverage in one of the world’s largest bus markets, and the biggest in Europe. Turkey’s intra-state bus market currently generates some 200 million ticket sales per year, corresponding to roughly $3 billion annually.

Currently, more than 300 bus operators compete in this highly fragmented market, which remains largely unconsolidated despite the 2019 acquisition of the country’s largest domestic bus operator by Flix.

Plans for Expansion in Post-Covid Era

Obilet now is equipped with plug-and-play B2B and SaaS solutions to be offered to both operators and online/offline ticket resellers in neighboring countries, where there is huge revenue potential for the Turkish start-up.

Obilet’s vastly enhanced market share, coupled with rising travel demand in the post-Covid era, is expected to yield 40 million ticket sales in 2022 and a GMV of over $500 million. Company officials even suggest that, as Obilet gradually expands into fresh markets, annual GMV could reach as much as $1 billion within the next few years.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press release

The disruption generated by AI enables the acceleration and industrialisation of the creation of internal solutions and start-ups through centres of excellence in Chicago, Madrid and Tbilisi.This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the depl

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press release

Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifoc

Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press release

Five-year contract to drive innovation in stimulation, intervention, digital and frac automationAgreement underscores gas as a pivotal fuel for global energy demand and a bridge to lower-carbon systems Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconve

Tabelog, Japan's Largest (*1)Restaurant Search and Reservation Service,Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press release

Experience Japan's Authentic Culinary Scene in Your Language — From Search to Reservation, All on Your SmartphoneRanked No. 1 in Downloads Among "Japanese Gourmet Search Apps" Chosen by International Travelers (*2) Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photo

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye